| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H21N3O |
| Molecular Weight | 295.3788 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN1C2=C(C=CC=C2)N(C)C3=C(C=CC=C3)C1=O
InChI
InChIKey=QPGGEKPRGVJKQB-UHFFFAOYSA-N
InChI=1S/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3
| Molecular Formula | C18H21N3O |
| Molecular Weight | 295.3788 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dibenzepin is a tricyclic antidepressant of the dibenzo-epine group. It is a selective noradrenaline uptake inhibitor, which exhibits in vitro and in vivo imipramine-like effects. It binds strongly to histamine H1 receptors in the brain and, to a lesser extent, to cholinergic receptors. The pharmacological profile of dibenzepin corresponds widely to its biochemical properties: histamine antagonism, tetrabenazine antagonism, potentiation of various noradrenergic effects and anticholinergic effects. Dibenzepin is only available in European countries for the treatment of depression.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
In adult patients, treatment should begin with Noveril (dibenzepin) 240 mg tablets, the daily dose being given as a single dose or in 2 divided dose.
Route of Administration:
Oral
